ASCO 2018

1-5 June | Booth #14112
 
Home /

Almac Diagnostic Services is attending ASCO 2018 in Chicago, Illinois, USA. You can find us at booth #14112


We would be delighted to chat to you about Almac Diagnostic Services Solutions for Multi-Arm Clinical Trial Designs 

• Novel strategy for patient stratification in Basket & Umbrella trials
• Solution enabling multiple biomarkers to be evaluated from one sample
• DNA & RNA cancer panels for research use and clinical trials
• Unique product offering for Immuno-Oncology
• Custom patient report enabling simple molecular data interpretation

You can learn more about Almac Diagnostic Services validation of the Illumina TruSight® Tumor 170 panel for prospective testing in clinical trials in the latest ClinicalOMICs Magazine.

Pick up a copy at ASCO or view online here.

ASCO 2018

 

When & Where

01st - 05th June 2018 - Chicago, IL

ASCO 2018

Meet the experts

Paul Harkin

Paul Harkin

President & Managing Director

Michael Sloan

Michael Sloan

Global VP of Commercial Operations

Richard Kennedy

Richard Kennedy

Global VP of Biomarker Discovery

Peter Kerr

Peter Kerr

VP of CDx Product Management

Nuala McCabe

Nuala McCabe

Head of Research

Laura Knight

Laura Knight

Head of Bioinformatics & Biostatistics

Katarina Wikstrom

Katarina Wikstrom

Head of US Operations

Kevin Ellison

Kevin Ellison

US Director of Business Development

Adam Gouldsworthy

Adam Gouldsworthy

EU Business Development Manager

Inigo Montes

Inigo Montes

EU Business Development Manager

Steve Walker

Steve Walker

Head of Product Management

Where can you find us?

We look forward to meeting you at booth #14112

Saturday June 2, 2018

1:15 PM - 4:45 PM

Laura Knight (Almac Diagnostics) - Exploration of the cGAS-STING pathway in prostate cancer.

Read more

Monday June 4, 2018

1:15 PM - 4:45 PM

Nuala McCabe (Almac Diagnostics) - Platinum based chemotherapy selects for PDGFRα dependent angiogenesis.

Read more

1:15 PM - 4:45 PM

Laura Knight (Almac Diagnostics) - Pan-cancer mesenchymal assay to predict response to MEK inhibitors.

Read more

Request a meeting at ASCO 2018

This website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies